Parellada, Eduard http://orcid.org/0000-0003-1131-4980
Gassó, Patricia http://orcid.org/0000-0001-6930-3454
Article History
Received: 28 October 2020
Revised: 9 April 2021
Accepted: 20 April 2021
First Online: 6 May 2021
Conflict of interest
: This work was partially supported by the Catalan Pons Balmes Grant (FCRB_PB_2018) and by the Spanish Ministry of Economy, Industry and Competitiveness, Carlos III Health Institute, Fondo de Investigación Sanitaria (FIS)—The European Regional Development Fund (FEDER – una manera de hacer Europa) (PI18/01005) and the Government of Catalonia, Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2017SGR1355; 2017SGR1562). E.P. has received honoraria and/or research grants from the Fondo de Investigación Sanitaria of the Spanish Ministry of Science and Innovation, MINECO, the Catalan Pons Balmes Grant, Fundació la Marató de TV3 of Catalonia, Janssen-Cilag, GlaxoSmithKline, Ferrer, and ADAMED. P.G. has received research grants from the Fondo de Investigación Sanitaria of the Spanish Ministry of Science and Innovation, the Catalan Pons Balmes Grant, and Janssen-Cilag. None of the authors received any payment from the pharmaceutical industry to write this article.